This inventor holds 9 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignees: Silenseed Ltd., Colorchip (Israel) Ltd., Radvision Ltd.. Active years: 2004-2018.
Location History:
- Herzeliya, IL (2014 - 2015)
- Herzliya, IL (2004 - 2018)
Company Filing History:
7 out of 7 
1 out of 4 
1 out of 18 
Years Active: 2004-2018
Title: Amotz Shemi: Innovator in RNA Interference Technologies
Introduction
Amotz Shemi is a prominent inventor based in Herzliya, Israel, known for his significant contributions to the field of RNA interference (RNAi) technologies. With a total of nine patents to his name, Shemi has made remarkable advancements in methods for treating various cancers, particularly prostate cancer.
Latest Patents
Among his latest patents is a groundbreaking work on RNA interference compositions targeting heat shock protein 90 (HSP90) and methods of use thereof. This disclosure relates to RNAi compositions that specifically target the expression of HSP90 in a subject. Additionally, he has developed polymeric delivery devices for providing these RNAi compositions, along with methods for treating cancer using the described compositions. Another notable patent focuses on the treatment of prostate cancer through regional and prolonged release of nucleotide-based RNAi agents.
Career Highlights
Throughout his career, Amotz Shemi has worked with several innovative companies, including Silenseed Ltd. and Radvision Ltd. His work has been instrumental in advancing the understanding and application of RNAi technologies in cancer treatment.
Collaborations
Shemi has collaborated with notable colleagues, including Elina Zorde Khvalevsky and Rachel Malka Gabai, contributing to the development of cutting-edge solutions in his field.
Conclusion
Amotz Shemi's contributions to RNA interference technologies and cancer treatment exemplify the impact of innovative thinking in the medical field. His patents and collaborations continue to pave the way for advancements in therapeutic approaches.